CURX
Income statement / Annual
Last year (2024), Curanex Pharmaceuticals Inc Common Stock's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Curanex Pharmaceuticals Inc Common Stock's net income was -$361.51 K.
See Curanex Pharmaceuticals Inc Common Stock,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
| Operating Revenue |
$0.00 |
$0.00 |
$26.00 K |
| Cost of Revenue |
$0.00
|
$0.00
|
$21.57 K
|
| Gross Profit |
$0.00
|
$0.00
|
$4.43 K
|
| Gross Profit Ratio |
0
|
0
|
0.17
|
| Research and Development Expenses |
$0.00
|
$0.00
|
$0.00
|
| General & Administrative Expenses |
$290.39 K
|
$19.30 K
|
$24.66 K
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$290.39 K
|
$19.30 K
|
$24.66 K
|
| Other Expenses |
$74.68 K
|
$0.00
|
$0.00
|
| Operating Expenses |
$365.06 K
|
$19.30 K
|
$24.66 K
|
| Cost And Expenses |
$365.06 K
|
$19.30 K
|
$46.23 K
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$0.00
|
$1.82 K
|
$21.16 K
|
| EBITDA |
-$290.39 K |
-$17.48 K |
$925.00 |
| EBITDA Ratio |
0
|
0
|
0.04
|
| Operating Income Ratio |
0
|
0
|
-0.78
|
| Total Other Income/Expenses Net |
$3.56 K
|
$100.00
|
$0.00
|
| Income Before Tax |
-$361.51 K
|
-$19.20 K
|
-$20.23 K
|
| Income Before Tax Ratio |
0
|
0
|
-0.78
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$361.51 K
|
-$19.20 K
|
-$20.23 K
|
| Net Income Ratio |
0
|
0
|
-0.78
|
| EPS |
-0.013 |
-0.0007 |
-0.02 |
| EPS Diluted |
-0.013 |
-0.0007 |
-0.02 |
| Weighted Average Shares Out |
$27.75 M
|
$42.00 M
|
$42.00 M
|
| Weighted Average Shares Out Diluted |
$27.75 M
|
$42.00 M
|
$42.00 M
|
| Link |
|
|
|
